ABS1114 RETENTION OF GOLIMUMAB TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS PRELIMINARY RESULTS OF AN INTERNATIONAL REAL-WORLD LIFE PANLARS REGISTER

Le résumé fourni par la source

Background: Golimumab has been widely used in the treatment of rheumatoid arthritis, but its retention rates and factors influencing its discontinuation remain under investigation. Objectives: To assess the golimumab retention rate during follow-up and to evaluate associated factors. Methods: Clinical, demographic and treatment data from the real-world life PANLAR´s register of consecutive rheumatoid arthritis patients treated with golimumab from Dec 2021 to Nov 2024 were analyzed. Descriptive statistics were used to summarize patients' characteristics. A Kaplan-Meier curve was created to assess drug survival, and a Cox regression analysis was performed to evaluate factors associated with golimumab retention. Results: We included 84 patients, predominantly women (84.5%, 95%CI:74.9-91.5), with a median age of 47.2 years (IQR: 37.6-55.5) and a disease duration of 7.4 years (IQR:1.9-12.5). 90.5% (95%CI:82.1-95.8) were seropositive for rheumatoid factor or anti-ACPA antibodies. Most patients had moderate to high disease activity at the initiation of the new treatment (DAS28ers>3.2 and DAS28crp>3.2 were 84.6% and 80.9% respectively) and were receiving corticosteroids (62.7%, 95%CI:50.6-72.3) and cDMARDs (85.7%, 95%CI:76.4-92.4) concomitantly. 56.6% (95%CI: 44.7-66.7) of patients had failed bDMARDs or tsDMARDs, primarily TNFi (80.8%, 95%CI: 66.7-90.8). The remaining variables of interest are summarized in Table 1. The drug retention rates (see Figure 1) were 97.6% (95% CI: 90.7-99.4), 89.1% (95% CI: 79.9-94.1), and 50.1% (95% CI: 38.4-60.6) at 3, 6, and 12 months, respectively. Although in the unadjusted Cox regression analysis, the presence of extra-articular manifestations (HR:1.9, p=0.01) and older age at treatment initiation (HR:1.03, p=0.02) were associated with lower drug survival, only the former variable (HR:2.19, p=0.03) remained significant in the adjusted analysis. The most common reason for discontinuation was loss of efficacy (61.5%, 95% CI: 31.6-86.1). Only one discontinuation due to an adverse event was reported. Conclusion: Approximately half of the patients with rheumatoid arthritis treated with golimumab remained on the drug at the end of the first year of follow-up. Only the presence of extra-articular manifestations was significantly associated with a higher risk of discontinuation. REFERENCES: NIL . Figure 1Persistence rates with golimumab treatment through 12 months for RA patients. Table 1Baseline characteristics and treatment patterns of RA patients.Golimumab (n=84)Prescription line, median (IQR)2 (1-3)-First line, n, % (95%CI)34, 40.4% (29.9-51.7)-Second line, n, % (95%CI)28, 33.3% (23.4-44.5)-Third line, n, % (95%CI)15, 17.9% (10.3-27.7)-Fourth line or beyond, n, % (95%CI)7, 8.4% (3.4-16.4)At least 1 cDMARD failure n, % (95%CI)83, 98.8% (93.5-99.9)At least 1 bDMARD failure n, % (95%CI)47, 56.6% (44.6-66.7)-TNFi, n, % (95%CI)38, 80.9% (66.7-90.8)-IL6i, n, % (95%CI)10, 21.3% (10.7-35.6)-CD80-86i, n, % (95%CI)17, 36.2% (22.6-51.4)-CD20i, n, % (95%CI)3, 6.4% (1.3-17.5)JAKi failure, n, % (95%CI)10, 11.9% (58.6-20.8)Extra-articular disease, n, % (95%CI)21, 25% (16.2-35.6)Bone erosión, n, % (95%CI)50, 59.5% (48.2-60.1)HAQ, mean (SD)1.13 (0.66)IQR: Interquartile range; SD: Standard deviation: CI: Confidence interval. Acknowledgements: This register received a irrestricted grant of Abbvie, Pfizer and Janssen. Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.